- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| So | RADIOPHARM THERANOSTICS LIMITED: RAD Completes Meeting with US FDA for Development of RAD101 | 3 | ASX | ||
| 01.10. | RADIOPHARM THERANOSTICS LIMITED: Notification of cessation of securities - RAD | - | ASX | ||
| 01.10. | RADIOPHARM THERANOSTICS LIMITED: Change of Director's Interest Notice (RC) | - | ASX | ||
| 30.09. | Radiopharm Theranostics Ltd - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 30.09. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 22.09. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| RADIOPHARM THERANOSTICS Aktie jetzt für 0€ handeln | |||||
| 22.09. | RADIOPHARM THERANOSTICS LIMITED: Change of Director's Interest Notices x 4 | 1 | ASX | ||
| 17.09. | RADIOPHARM THERANOSTICS LIMITED: Notification regarding unquoted securities - RAD | - | ASX | ||
| 17.09. | RADIOPHARM THERANOSTICS LIMITED: RADOC New Class Options Range of Units and Top 20 Holders | 1 | ASX | ||
| 17.09. | RADIOPHARM THERANOSTICS LIMITED: Application for quotation of securities - RAD | 1 | ASX | ||
| 17.09. | RADIOPHARM THERANOSTICS LIMITED: Application for quotation of securities - RAD | 1 | ASX | ||
| 17.09. | RADIOPHARM THERANOSTICS LIMITED: Share purchase plan completed | 3 | ASX | ||
| 14.09. | Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 14.09. | RADIOPHARM THERANOSTICS LIMITED: RAD oral presentation at SNO26 on RAD101 Phase IIb data | - | ASX | ||
| 11.09. | RADIOPHARM THERANOSTICS LIMITED: Results of Meeting | 2 | ASX | ||
| 09.09. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 09.09. | Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma | 269 | GlobeNewswire (Europe) | Positive safety and favourable biodistribution seen in all subjects dosed Imaging data in all evaluable pancreatic cancer patients demonstrated significant tumor uptake Data support the... ► Artikel lesen | |
| 09.09. | RADIOPHARM THERANOSTICS LIMITED: RAD Announces Positive Data from RAD301 P1 Imaging Trial | 1 | ASX | ||
| 28.08. | RADIOPHARM THERANOSTICS LIMITED: Appendix 4E and Preliminary Final Report | - | ASX | ||
| 27.08. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings |
1 2 3 4 5 Weiter >>
92 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,548 | -0,89 % | Valneva: Großbritannien entzieht Chikungunya-Impfstoff die Zulassung | Valneva verliert in Großbritannien die Marktzulassung für seinen Chikungunya-Impfstoff IXCHIQ. Die britische Arzneimittelbehörde MHRA hat die Genehmigung nach einer erneuten Nutzen-Risiko-Bewertung... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 8,510 | -1,05 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| OCUGEN | 0,851 | -0,23 % | Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate | European Affiliate, based in Amsterdam, to support upcoming marketing authorization submissions, OCU410 Phase 3 development program, and potential commercialization in Europe MALVERN, Pa., Oct. 06... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,040 | +0,48 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,920 | -0,13 % | Jim Cramer Explains His Hesitation Over Sarepta (SRPT) Therapeutics | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,151 | +3,61 % | Pacific Biosciences Collaborates With TychoBio For AI-powered RNA Data Creation; Shares Up | ||
| REDHILL BIOPHARMA | 0,539 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 6,800 | +0,74 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VERASTEM | 7,144 | -4,70 % | Verastem stock maintained at Buy by BTIG ahead of data readout | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,462 | 0,00 % | Volta Labs launches automated library preparation solution for the Oxford Nanopore Ligation Sequencing Kit V14 | BOSTON, May 21, 2026 /PRNewswire/ -- Volta Labs, maker of the Callisto Sample Prep System, today announced the availability of its DNA Library Preparation Application for the Oxford Nanopore... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 2,174 | 0,00 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,330 | +1,75 % | Rocket Pharma upgraded at Goldman Sachs on Danon disease therapy | ||
| PALISADE BIO | 1,535 | -0,32 % | Raymond James nimmt Coverage für Palisade Bio mit "Outperform" auf | ||
| TVARDI THERAPEUTICS | 0,975 | +5,41 % | Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update | Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations... ► Artikel lesen | |
| XBIOTECH | 1,810 | +0,22 % | XBiotech Inc.: XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis | IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment
AUSTIN, Texas, June 15, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:... ► Artikel lesen |
RADIOPHARM THERANOSTICS LIMITED ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,130 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RADIOPHARM THERANOSTICS LIMITED ADR finden Sie auf Wallstreet Online.